Research programme: neurodegenerative diseases therapeutics - Cognition Therapeutics
Alternative Names: amyloid beta-protein inhibitors - Cognition Therapeutics; CT 0093; CT 0109; CT 013441; CT 013461Latest Information Update: 28 Apr 2022
At a glance
- Originator Cognition Therapeutics
- Class Antidementias; Antiparkinsonians; Small molecules
- Mechanism of Action Alpha-synuclein inhibitors; Amyloid beta-protein inhibitors; Progesterone receptor antagonists; Sigma-2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Alzheimer's disease; Parkinson's disease
Most Recent Events
- 28 Apr 2022 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA
- 28 Apr 2022 No recent reports of development identified for preclinical development in Parkinson's-disease in USA
- 30 Mar 2020 Preclinical development is still underway in USA for Alzhemier's disease